Kestra Private Wealth Services LLC lowered its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 29.4% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 784 shares of the medical research company’s stock after selling 326 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Bio-Rad Laboratories were worth $442,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors also recently modified their holdings of the business. EP Wealth Advisors LLC bought a new position in Bio-Rad Laboratories in the 1st quarter valued at $218,000. BNP Paribas Arbitrage SA grew its holdings in Bio-Rad Laboratories by 100.2% during the first quarter. BNP Paribas Arbitrage SA now owns 15,856 shares of the medical research company’s stock valued at $8,931,000 after purchasing an additional 7,935 shares during the period. Gabelli Funds LLC increased its position in Bio-Rad Laboratories by 1.0% in the first quarter. Gabelli Funds LLC now owns 28,800 shares of the medical research company’s stock worth $16,221,000 after buying an additional 295 shares during the last quarter. Worldquant Millennium Advisors LLC lifted its position in shares of Bio-Rad Laboratories by 20.2% during the 1st quarter. Worldquant Millennium Advisors LLC now owns 9,012 shares of the medical research company’s stock valued at $5,076,000 after buying an additional 1,512 shares during the last quarter. Finally, Walleye Capital LLC grew its stake in shares of Bio-Rad Laboratories by 728.0% during the 1st quarter. Walleye Capital LLC now owns 8,644 shares of the medical research company’s stock worth $4,869,000 after acquiring an additional 7,600 shares during the period. 64.33% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several equities research analysts have commented on the stock. Citigroup dropped their price objective on shares of Bio-Rad Laboratories from $750.00 to $700.00 and set a “buy” rating on the stock in a report on Friday, July 8th. Credit Suisse Group initiated coverage on shares of Bio-Rad Laboratories in a report on Wednesday, August 24th. They issued an “outperform” rating and a $715.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Bio-Rad Laboratories presently has an average rating of “Moderate Buy” and an average target price of $705.00.
Insider Activity at Bio-Rad Laboratories
Bio-Rad Laboratories Stock Down 0.7 %
BIO stock opened at $445.50 on Tuesday. Bio-Rad Laboratories, Inc. has a 1-year low of $437.13 and a 1-year high of $804.65. The stock has a market cap of $13.23 billion, a price-to-earnings ratio of -6.72 and a beta of 0.99. The company has a current ratio of 5.30, a quick ratio of 4.22 and a debt-to-equity ratio of 0.13. The company’s 50 day moving average is $510.35 and its 200 day moving average is $522.60.
Bio-Rad Laboratories (NYSE:BIO – Get Rating) last announced its earnings results on Thursday, July 28th. The medical research company reported $3.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.46 by $0.92. Bio-Rad Laboratories had a negative net margin of 67.66% and a positive return on equity of 3.82%. The company had revenue of $691.10 million during the quarter, compared to analyst estimates of $664.60 million. During the same period in the previous year, the business earned $3.54 earnings per share. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. Sell-side analysts predict that Bio-Rad Laboratories, Inc. will post 14.35 EPS for the current fiscal year.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.
- Get a free copy of the StockNews.com research report on Bio-Rad Laboratories (BIO)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.